Elevai Labs (NASDAQ: ELAB) Resolves Nasdaq Compliance Issues and Announces Subsidiary Name Changes

Elevai Labs announced key developments in a recent 8-K SEC filing, detailing the resolution of compliance issues with Nasdaq and significant name changes within its subsidiary companies. As per the filing, Elevai Labs received a Bid Price Deficiency Letter from Nasdaq on November 7, 2024, allowing the company to rectify its bid price non-compliance under […]

Leave a Reply

Your email address will not be published.

Previous post Vincerx Pharma Terminates Sales Agreement with Leerink Partners LLC and Holds Special Meeting of Stockholders
Next post RF Industries (NASDAQ:RFIL) Reports Fourth Quarter and Fiscal Year 2024 Financial Results